Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On ...
Vertex Pharmaceuticals VRTX announced positive data from an interim analysis of the ongoing phase III RAINER study, which evaluated its investigational drug povetacicept for IgA nephropathy (IgAN) ...
Vertex Pharmaceuticals has a rolling biologics license application with the FDA for povetaciceptin IgA nephropathy. With new data from RAINIER, the biotech expects to complete its submission by the ...
Investor's Business Daily on MSN
IBD stock of the day: Ligand Pharma, biotech's royalty arm, breaks out
Ligand Pharmaceuticals is Tuesday's IBD Stock Of The Day. The biotech stock has blown past several buy points on its way to a new breakout.
Opinion
5dOpinion
Surge to Save Newborns Coalition Launches with New Study Showing Cost to End State-by-State Newborn Screening Variability
The new study estimated it would cost $173 million to implement all RUSP-approved conditions across all 50 states, including those added in late 2025 and two anticipated future conditions.
Tasting Table on MSN
15 Of The Oldest Pubs In Ireland
These Irish pubs have kept their doors open for centuries and proudly wear their age on their walls, all while serving up delicious pints of Guinness.
Detailed price information for Enanta Pharmaceutica (ENTA-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results